Though no previous study has explored the changes of miR-29b in the brains of AD patients, we believe that SIRT1/PGC-1α (FNDC5) may be a possible drug target to prevent patients with ARHL from developing AD. This evidence concerns the gene PPARGC1A and Alzheimer disease.